Business Update
Company gets orphan drug designation for Prestara
Published in Medical Letter on the CDC and FDA, July 24th, 2005
The United States Food and Drug Administration (FDA) has confirmed to the company the indication "prevention of loss of bone mineral density in systemic lupus erythematosus patients on glucocorticoids" qualifies for orphan drug exclusivity under the original orphan drug designation previously received by the company.
In October, 2004, Genelabs announced that preliminary results of clinical trial GL02-01 in women with lupus did not show statistical significance for the primary endpoint, absolute change in bone mineral density...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Environmental Health
National exposure measurements to protect public health released - HIV/AIDS Therapy
Natural resistance of HIV type 2 to zidovudine described - Human Papillomavirus
Gene expression profile of cervical cells harboring HPV-16 reported - Listeriosis
Outbreak of listeriosis in U.S. traced to contaminated hot dogs - Pap Test
Physician recommendation improves likelihood of Pap testing - Acinetobacter Baumannii
Imipenem-resistant A. baumannii outbreak produced OXA-23 beta-lactamase - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
